Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to compare the effectiveness and safety of CAM2029 to octreotide LAR or lanreotide ATG in patients with advanced, well-differentiated GEP-NET. Patients who experience progressive disease in the randomized part of the study may proceed to an open-label extension part with intensified treatment with CAM2029.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05050942
Study type Interventional
Source Camurus AB
Contact
Status Active, not recruiting
Phase Phase 3
Start date October 22, 2021
Completion date December 2026

See also
  Status Clinical Trial Phase
Withdrawn NCT04614766 - A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors Phase 1/Phase 2
Completed NCT03220217 - To Evaluate the Optimal Dose of 68Ga-OPS202 as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET) Phase 2
Recruiting NCT03475953 - A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors Phase 1/Phase 2
Recruiting NCT06253897 - A Study to Understand Participant's Experiences in Gastro-enteropancreatic Neuroendocrine Tumors (GEP-NETs) and Acromegaly
Recruiting NCT03863106 - The Lyon Real World Evidence in Metastatic NeuroEndocrine Tumours
Active, not recruiting NCT03972488 - Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET Phase 3
Terminated NCT03042780 - FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas Phase 2
Active, not recruiting NCT03600233 - Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors Phase 2
Completed NCT01423734 - The Reproducibility Of Diffusion Weighted Magnetic Resonance Imaging For Neuroendocrine Tumor Liver Metastases
Withdrawn NCT02779257 - Pasireotide Treatment for Neuroendocrine Tumor Phase 4